Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma

摘要: BACKGROUNDActivation in RAS pathway has been associated with cancer development. The oncogenes of RAS family (NRAS, KRAS and HRAS) are frequently mutated across various cancer types, where NRAS mutations are present in 15-20% of melanomas. NRAS-mutant melanomas (NRASm) have been extensively characterized. However, molecular and clinical implications of HRAS mutations (HRASm) in melanoma are less well understood.